Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases

Proteomics technologies are often used for the identification of protein targets of the immune system. Here, we discuss the immunoproteomics technologies used for the discovery of autoantigens in autoimmune diseases where immune system dysregulation plays a central role in disease onset and progress...

Full description

Bibliographic Details
Main Authors: Ganesan Vinitha, Ascherman Dana P., Minden Jonathan S.
Format: Article
Language:English
Published: De Gruyter 2016-05-01
Series:Biomolecular Concepts
Subjects:
Online Access:https://doi.org/10.1515/bmc-2016-0007
id doaj-5ad0cf789c4d44a9a05f0877a6ca5bab
record_format Article
spelling doaj-5ad0cf789c4d44a9a05f0877a6ca5bab2021-09-05T20:42:35ZengDe GruyterBiomolecular Concepts1868-50211868-503X2016-05-017213314310.1515/bmc-2016-0007Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseasesGanesan Vinitha0Ascherman Dana P.1Minden Jonathan S.2Department of Biological Sciences, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA 15213, USADivision of Rheumatology, Department of Medicine, University of Miami Miller School of Medicine, 1600 Northwest 10th Avenue, Miami, FL 33136, USADepartment of Biological Sciences, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA 15213, USAProteomics technologies are often used for the identification of protein targets of the immune system. Here, we discuss the immunoproteomics technologies used for the discovery of autoantigens in autoimmune diseases where immune system dysregulation plays a central role in disease onset and progression. These autoantigens and associated autoantibodies can be used as potential biomarkers for disease diagnostics, prognostics and predicting/monitoring drug responsiveness (theranostics). Here, we compare a variety of methods such as mass spectrometry (MS)-based [serological proteome analysis (SERPA), antibody mediated identification of antigens (AMIDA), circulating immune complexome (CIC) analysis, surface enhanced laser desorption/ionization-time of flight (SELDI-TOF)], nucleic acid based serological analysis of antigens by recombinant cDNA expression cloning (SEREX), phage immunoprecipitation sequencing (PhIP-seq) and array-based immunoscreening (proteomic microarrays), luciferase immunoprecipitation systems (LIPS), nucleic acid programmable protein array (NAPPA) methods. We also review the relevance of immunoproteomic data generated in the last 10 years, with a focus on the aforementioned MS based methods.https://doi.org/10.1515/bmc-2016-0007amidaautoantibodiesautoantigensautoimmune diseasesbiomarkersimmunoproteomicsserpa
collection DOAJ
language English
format Article
sources DOAJ
author Ganesan Vinitha
Ascherman Dana P.
Minden Jonathan S.
spellingShingle Ganesan Vinitha
Ascherman Dana P.
Minden Jonathan S.
Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
Biomolecular Concepts
amida
autoantibodies
autoantigens
autoimmune diseases
biomarkers
immunoproteomics
serpa
author_facet Ganesan Vinitha
Ascherman Dana P.
Minden Jonathan S.
author_sort Ganesan Vinitha
title Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
title_short Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
title_full Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
title_fullStr Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
title_full_unstemmed Immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
title_sort immunoproteomics technologies in the discovery of autoantigens in autoimmune diseases
publisher De Gruyter
series Biomolecular Concepts
issn 1868-5021
1868-503X
publishDate 2016-05-01
description Proteomics technologies are often used for the identification of protein targets of the immune system. Here, we discuss the immunoproteomics technologies used for the discovery of autoantigens in autoimmune diseases where immune system dysregulation plays a central role in disease onset and progression. These autoantigens and associated autoantibodies can be used as potential biomarkers for disease diagnostics, prognostics and predicting/monitoring drug responsiveness (theranostics). Here, we compare a variety of methods such as mass spectrometry (MS)-based [serological proteome analysis (SERPA), antibody mediated identification of antigens (AMIDA), circulating immune complexome (CIC) analysis, surface enhanced laser desorption/ionization-time of flight (SELDI-TOF)], nucleic acid based serological analysis of antigens by recombinant cDNA expression cloning (SEREX), phage immunoprecipitation sequencing (PhIP-seq) and array-based immunoscreening (proteomic microarrays), luciferase immunoprecipitation systems (LIPS), nucleic acid programmable protein array (NAPPA) methods. We also review the relevance of immunoproteomic data generated in the last 10 years, with a focus on the aforementioned MS based methods.
topic amida
autoantibodies
autoantigens
autoimmune diseases
biomarkers
immunoproteomics
serpa
url https://doi.org/10.1515/bmc-2016-0007
work_keys_str_mv AT ganesanvinitha immunoproteomicstechnologiesinthediscoveryofautoantigensinautoimmunediseases
AT aschermandanap immunoproteomicstechnologiesinthediscoveryofautoantigensinautoimmunediseases
AT mindenjonathans immunoproteomicstechnologiesinthediscoveryofautoantigensinautoimmunediseases
_version_ 1717785391921102848